Cover Story: PHARMACEUTICAL REBATES ON THE HOT SEAT

The decision makes the therapy the first and only twice-yearly option available in the United States for PrEP.

Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.

Researchers explored the incidence of pneumococcal hemolytic uremic syndrome in children living in Sweden from January 2009 to December 2024.

In this episode, Natalie DiPietro Mager, PharmD, PhD speaks with David Bright, PharmD, MBA, professor at Ferris State University College of Pharmacy.

The program will include branded obesity glucagon-like peptide-1 medications, which will have a transparent monthly cost.

Topline results from a phase 3 trial showed 64.1% of patients on atogepant achieved a 50% or greater reduction in mean monthly migraine days during months 4 to 6.